Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rimantadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A2 | O15244 | 2/20 | 1.00 |
| ▸ | SLC47A1 | Q96FL8 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 0.95 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.46 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.46 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.46 |
| ▸ | DPP4 | P27487 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | STAT6 | P42226 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rimantadine SCHEMBL15532385 | 1.00 | SLC22A2 (1.00) | SLC22A2SLC47A1MAPTNPC1ALDH1A1 | |
| Rimantadine SCHEMBL29908943 | 1.00 | SLC22A2 (1.00) | SLC22A2SLC47A1MAPTNPC1ALDH1A1 | |
| Rimantadine SCHEMBL20409367 | 1.00 | SLC22A2 (1.00) | SLC22A2SLC47A1MAPTNPC1ALDH1A1 | |
| Rimantadine SCHEMBL2982 | 1.00 | SLC22A2 (1.00) | SLC22A2SLC47A1MAPTNPC1ALDH1A1 | |
| Rimantadine SCHEMBL4366035 | 0.97 | MAPT (1.00) | SLC22A2SLC47A1MAPTNPC1ALDH1A1 | |
| Rimantadine SCHEMBL28108817 | 0.97 | MAPT (1.00) | SLC22A2SLC47A1MAPTNPC1ALDH1A1 | |
| Rimantadine SCHEMBL40906 | 0.97 | MAPT (1.00) | SLC22A2SLC47A1MAPTNPC1ALDH1A1 | |
| Rimantadine SCHEMBL14973619 | 0.95 | SLC22A2 (0.90) | SLC22A2SLC47A1MAPTNPC1ALDH1A1 | |
| Rimantadine SCHEMBL3719331 | 0.91 | SLC22A2 (0.82) | SLC22A2SLC47A1MAPTNPC1ALDH1A1 | |
| Rimantadine SCHEMBL1074987 | 0.91 | SLC22A2 (0.82) | SLC22A2SLC47A1MAPTNPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 27623 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| EP-4094767-B1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-20 | — | — | EP | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| EP-3790536-B1 | NANOCONTAINERS FOR TRANSPORTING NONPOLAR, LIPOPHILIC SUBSTANCES SUCH AS ANTIBIOTICS | KARLSRUHER INST TECHNOLOGIE (DE) | 2026-04-22 | — | — | EP | claimed |
| EP-4729063-A2 | TREATMENT OF CANCER USING COENZYME Q10 COMBINATION THERAPIES | BPGbio, Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| US-20260102422-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-04-16 | — | — | US | claimed |
| US-12599644-B2 | Treatment of coronavirus infection with Flt3 receptor interacting lectin (FRIL) | ACADEMIA SINICA (TW) | 2026-04-14 | — | — | US | claimed |
| US-12595280-B2 | Phosphoramidates for the treatment of hepatitis B virus | EMORY UNIVERSITY (US) | 2026-04-07 | — | — | US | claimed |
| US-12594280-B2 | Antiviral compositions for treating the flu | UNIVERSITE CLAUDE BERNARD LYON 1 (FR) | 2026-04-07 | — | — | US | claimed |
| WO-1992000988-A1 | TARGETED DRUG DELIVERY VIA PHOSPHONATE DERIVATIVES | BODOR NICHOLAS S (US) | 1992-01-23 | — | — | WO | claimed |
| US-5049389-A | Non-phospholipd lipid, delivery by inhalation | LIPOSOME TECHNOLOGY, INC. (US) | 1991-09-17 | — | — | US | claimed |
| WO-1991010427-A2 | THE EFFECT OF TRANSGLUTAMINASE INHIBITION ON MICROFILARIAE DEVELOPMENT AND MACROFILARIAE VIABILITY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1991-07-25 | — | — | WO | claimed |
| WO-1990006775-A1 | A NOVEL NONPHOSPHOLIPID LIPOSOME COMPOSITION FOR SUSTAINED RELEASE OF DRUGS | LIPOSOME TECHNOLOGY, INC. (US) | 1990-06-28 | — | — | WO | claimed |
| EP-0162444-B1 | PROCESS FOR PREPARING RIMANTADINE | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-03-28 | — | — | EP | claimed |
| EP-0178668-A2 | Process for preparing rimantadine | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1986-04-23 | — | — | EP | claimed |
| EP-0162444-A2 | Process for preparing rimantadine | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-11-27 | — | — | EP | claimed |
| US-4551552-A | Process for preparing rimantadine | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-11-05 | — | — | US | claimed |
| EP-0038629-A1 | Virazole derivatives, process for their preparation and use as antiviral agents | BEECHAM GROUP PLC (GB) | 1981-10-28 | — | — | EP | claimed |
| US-4289773-A | ETHYL 6,7-DIBROMO-3,4-DIHYDRO-3-OXOQUINOXALINE CARBOXYLATE AND A HINDERED AMINE | ELI LILLY AND COMPANY (US) | 1981-09-15 | — | — | US | claimed |